XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialXTL Biopharmaceuticals Sponsored ADR ( (XTLB) ) has provided an announcement. On December 30, 2025, XTL Biopharmaceuticals reported financial results for the six months ended June 30, 2025, highlighting a near-full write-down of its subsidiary The Social Proxy following a prolonged dispute with the unit’s former shareholders and the resignation of its key executives earlier in December 2025. The impairment of The Social Proxy’s intangible assets and goodwill drove substantial non-cash charges, including increases in cost of services and sales and marketing expenses and a $3.2 million goodwill impairment, which contributed to a sharp widening of the net loss to $5.5 million from $0.2 million a year earlier. While revenue reached $0.5 million for the period due to consolidating The Social Proxy for the first time, XTL’s liquidity weakened as cash and marketable securities fell to about $0.25 million, and the company noted that no updated data had been received from the subsidiary after June 30, 2025. The company also recorded significant finance income from the cancellation and revaluation of warrant liabilities related to The Social Proxy transaction, and, despite a post–first half 2025 legal claim and ongoing disputes with the former shareholders, it concluded that no litigation provision was warranted at this stage, underscoring continued uncertainty over the strategic and financial value of the acquisition. Spark’s Take on XTLB Stock According to Spark, TipRanks’ AI Analyst, XTLB is a Underperform. XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain. To see Spark’s full report on XTLB stock, click here. More about XTL Biopharmaceuticals Sponsored ADR XTL Biopharmaceuticals Ltd., listed on Nasdaq and the Tel Aviv Stock Exchange, is an Israel-based biopharmaceutical company that operates through its wholly owned subsidiary, The Social Proxy, and holds financial assets including shares of InterCure Ltd. Its activities encompass biopharma-related operations alongside digital-service revenues consolidated from The Social Proxy following its acquisition in August 2024. Average Trading Volume: 836,341 Technical Sentiment Signal: Sell Current Market Cap: $7.14M